Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jennifer Popovsky

MOHS-Micrographic Surgery Medina, OH Medical Doctor

NPI 1952307324 CMS profile 178722

1133 Medina Rd Ste 100, Medina, OH 44256

Open in the dashboard

General payments

$14,609

264 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jennifer Popovsky of Medina, OH is reported in the CMS Open Payments database as having received $14,609 across 264 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 92nd percentile of MOHS-Micrographic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $773 36
2024 General $1,101 52
2023 General $605 25
2022 General $938 32
2021 General $528 26
2020 General $6,567 27
2019 General $4,097 66

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jennifer Popovsky
  • MOHS-Micrographic Surgery median
  • Middle half of MOHS-Micrographic Surgery
  • National median

In program year 2025, general payments to Jennifer Popovsky were reported at $773. Among 1,077 MOHS-Micrographic Surgery profiles paid that year, the median was $465 and the middle half received between $145 and $1,066.

Show as a table
Year Jennifer Popovsky MOHS-Micrographic Surgery median Middle half National median
2019 $4,097 $316 $106–$785 $163
2020 $6,567 $162 $68–$412 $114
2021 $528 $243 $87–$654 $132
2022 $938 $300 $102–$887 $149
2023 $605 $364 $125–$1,010 $160
2024 $1,101 $445 $142–$1,108 $164
2025 $773 $465 $145–$1,066 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genentech USA, Inc. $9,247 13 payments
  2. Regeneron Healthcare Solutions, Inc. $669 24 payments
  3. Janssen Biotech, Inc. $588 29 payments
  4. AbbVie, Inc. $559 28 payments
  5. Biofrontera Inc. $457 15 payments
  6. Genzyme Corporation $383 17 payments
  7. Lilly USA, LLC $325 14 payments
  8. Sun Pharmaceutical Industries Inc. $298 14 payments
  9. MIMEDX Group, Inc. $278 24 payments
  10. E.R. Squibb & Sons, L.L.C. $159 3 payments
  11. Other $1,647 83 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,160 2 payments
  2. Food and Beverage $5,537 261 payments
  3. Travel and Lodging $912 1 payment
Products named General payments · program years 2019–2025
  1. Erivedge $9,247 13 payments
  2. LIBTAYO $452 18 payments
  3. XEPI $442 14 payments
  4. BF-RhodoLED $423 12 payments
  5. TREMFYA $421 20 payments
  6. AMELUZ $392 10 payments
  7. TALTZ $325 14 payments
  8. SKYRIZI $280 12 payments
  9. DUPIXENT $273 13 payments
  10. ILUMYA $186 7 payments
  11. Other $3,734 176 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 12 drugs

Part D claims

589

Median for Dermatology: 534

Drug cost

$8,009

Median for Dermatology: $67,151

Branded share of claims

6.6%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Fluorouracil Generic 35 $2,390
Doxycycline Hyclate Generic 355 $2,026
Acitretin Generic 11 $1,724
Imiquimod Generic 13 $451
Econazole Nitrate Generic 12 $450
Triamcinolone Acetonide Generic 36 $337
Clobetasol Propionate Generic 13 $247
Ciprofloxacin Hcl Generic 21 $112
Cephalexin Generic 27 $106
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 39 $84

The 10 drugs with the highest cost, of 12 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 90 billing codes

Paid by Medicare

$393,629

Of which drugs: $88,062

Medicare patients

501

Average age 76

Services billed

8,871

234 women, 267 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 46%
Ischemic heart disease 31%
Diabetes 23%
Chronic kidney disease 23%
Atrial fibrillation 21%
Cancer 20%
Heart failure 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Epifix, per square centimeter Q4186 Office 11 517 $62,371
Aminolevulinic acid hcl for topical administration, 10% gel, 10 mg J7345 Office 23 6,800 $8,649

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 11 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TREMFYA
  • Janssen Biotech, Inc. $218
$218 — —
DUPIXENT
  • GENZYME CORPORATION $71
  • Regeneron Healthcare Solutions, Inc. $27
$98 — —
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $67
$67 — —
OPZELURA
  • Incyte Corporation $53
$53 — —
Bimzelx
  • UCB, Inc. $52
$52 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 11 in the dashboard with a free account

Records

264 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other MOHS-Micrographic Surgery in Ohio

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record